Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application

Area of Science:

• Immunology
• Vaccinology
• Infectious Diseases

Background:

• Tuberculosis (TB) and leprosy are significant public health issues, particularly in low-income nations.
• Current control strategies rely on diagnostics and vaccines, with limited efficacy for existing TB vaccines.
• Bacille Calmette-Guérin (BCG), the sole TB vaccine, impacts leprosy but offers inconsistent TB protection.

Purpose of the Study:

• To review preclinical and clinical studies of vaccines for TB and leprosy.
• To explore the potential for new TB vaccines to provide cross-protection against leprosy.
• To present preclinical evidence for cross-protective efficacy of a novel recombinant protein vaccine.

Main Methods:

• Review of existing literature on mycobacterial vaccine research.
• Analysis of TB vaccine candidates for shared antigens with Mycobacterium leprae.
• Preclinical evaluation of a fusion recombinant protein vaccine (Ag85B-ESAT6) in mouse models.

Main Results:

• New TB subunit vaccines often contain antigens homologous to M. leprae.
• Preclinical studies showed cross-protection against both M. tuberculosis and M. leprae using the Ag85B-ESAT6 fusion protein.
• The development of vaccines targeting both diseases is feasible.

Conclusions:

• New TB vaccines hold promise for cross-protection against leprosy.
• Integrated research and global strategies are needed for developing dual-protection vaccines.
• Further development of combined TB-leprosy vaccines could significantly impact disease control.